Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBT-020 in early stage Huntington's disease
NL-OMON45299Phase 2Active, not recruiting
- Sponsor
- Stealth BioTherapeutics
- Start
- Mar 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington disease (HD) comparing SBT-020 with Placebo (2 arms). Primary endpoints: Adverse events leading to premature discontinuation of study drug, Treatment-emergent serious and non-serious adverse events and 3 more. Started Mar 2017; status: active, not recruiting.
02
Drugs
SBT-20
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON45299.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45299.